Response to Comments: MolDX: Breast Cancer IndexTM (BCI) Gene Expression Test

This record (A56283) is a Response to Comments regarding the MolDX Breast Cancer Index™ (BCI) Gene Expression Test and provides administrative dates (comment period, notice period, LCD finalization) but does not include clinical coverage, coding, or claim documentation criteria. For actionable coverage criteria, documentation requirements, ICD-10 mappings, and frequency limits, consult the referenced LCD DL37832. This extraction is limited by the absence of coverage text in the provided document and requires manual review of DL37832.

"This document is a Response to Comments for MolDX: Breast Cancer Index™ (BCI) Gene Expression Test (LCD DL37832). Comment period: 2018-11-15 to 2018-12-29; notice period: 2019-02-14 to 2019-03-31; ..."

Sign up to see full coverage criteria, indications, and limitations.